HC Wainwright restated their buy rating on shares of DiaMedica Therapeutics (NASDAQ:DMAC - Free Report) in a research report released on Friday morning,Benzinga reports. The brokerage currently has a $7.00 price objective on the stock.
Separately, Oppenheimer reiterated an "outperform" rating and set a $6.00 price target on shares of DiaMedica Therapeutics in a report on Friday, August 16th.
View Our Latest Stock Analysis on DMAC
DiaMedica Therapeutics Trading Down 2.7 %
Shares of NASDAQ:DMAC traded down $0.11 during trading on Friday, reaching $4.01. The stock had a trading volume of 75,699 shares, compared to its average volume of 49,986. The company has a market capitalization of $171.43 million, a P/E ratio of -7.36 and a beta of 1.46. The firm's 50-day simple moving average is $4.30 and its 200 day simple moving average is $3.56. DiaMedica Therapeutics has a one year low of $2.14 and a one year high of $4.95.
Institutional Trading of DiaMedica Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of DiaMedica Therapeutics during the third quarter valued at $40,000. Magnolia Capital Advisors LLC purchased a new position in shares of DiaMedica Therapeutics during the second quarter valued at $87,000. Blue Trust Inc. purchased a new position in shares of DiaMedica Therapeutics during the third quarter valued at $185,000. Finally, Vanguard Group Inc. grew its holdings in shares of DiaMedica Therapeutics by 26.3% during the first quarter. Vanguard Group Inc. now owns 1,013,522 shares of the company's stock valued at $2,807,000 after buying an additional 211,351 shares in the last quarter. Institutional investors own 10.12% of the company's stock.
About DiaMedica Therapeutics
(
Get Free Report)
DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.
Featured Articles
Before you consider DiaMedica Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DiaMedica Therapeutics wasn't on the list.
While DiaMedica Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
